Pharmacokinetics/ADME of large molecules

Preclinical Drug Development

Volumn , Issue , 2005, Pages 159-198

  Braeckman, Rene ^a  

^a Valeant Pharmaceuticals International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952068648     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Bocci V. Metabolism of anticancer agents. Pharmacol Ther 1987; 34:1-49.
2. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Del Rev 1990; 4:149-169.
3. Lee VHL. Enzymatic barriers to peptide and protein absorption. CRC Crit Rev Ther Drug Carrier Syst 1988; 5:69-97.
4. Ferraiolo BL, Mohler MA. Goals and analytical methodologies for protein disposition studies. In: In: Ferraiolo BL, Mohler MA, Gloff CA, eds. Protein Pharmacokinetics and Metabolism. New York: Plenum Press, 1992.
5. Gibbons JA, Luo Z-P, Hannon ER, Braeckman RA, Young JD. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated rats. J Pharmacol Exp Ther 1995; 272:119-125.
6. Bauer RJ, Gibbons JA, Bell DP, Luo Z-P, Young JD. Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exper Ther 1994; 268:152-158.
7. Mordenti J, Chen SC, Ferraiolo BL. Pharmacokinetics of interferon-gamma. In: In: Kung AHC, Baughman RA, Larrick JW, eds. Therapeutic Proteins. Pharmacokinetics and Pharmacodynamics. New York: W.H. Freeman and Company, 1992:187-199.
8. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low-molecular weight protein: a review. Kidney Int 1979; 16:251-270.
9. Takakura Y, Fujita T, Hashida M, Sesaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 1990; 7:339-346.
10. Kompella UB, Lee VHL. Pharmacokinetics of peptide and protein drugs. In: In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 1991:391-484.
11. Rabkin R, Dahl DC. Renal uptake and disposal of proteins and peptides. In: In: Audus KL, Raub TJ, eds. Biological Barriers to Protein Delivery. New York: Plenum Press, 1993:299-338.
12. Maack T, Park CH, Camergo MJF. Renal filtration, transport, and metabolism of proteins. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. New York: Raven Press, 1985:1173-1803.
13. Wall DA, Maack T. Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 1985; 248:C12-C20.
14. Ohnishi H, JTYC, Lin KK, Lee H, Chu TM. Role of the kidney in metabolic change of interleukin-2. Tumor Biol 1989; 10:202-214.
15. Maack T. Renal handling of low molecular weight proteins. Am J Med 1975; 58:57-64.
16. Ganapathy V, Leibach FH. Carrier-mediated reabsorption of small peptides in renal proximal tubule. Am J Physiol 1986; 25:F945-F953.
17. Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol 1980; 238:F151-F158.
18. Rabkin R, Kitaji J. Renal metabolism of peptide hormones. Mineral Electrolyte Metab 1983; 9:212-226.
19. Hellfritzsch M, Nielsen S, Christensen EI, Nielsen JT. Basolateral tubular handling of insulin in the kidney. Contrib Nephrol 1988; 68:86-91.
20. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologica 1984; 27:351-357.
21. Meijer DKF, Ziegler K. Mechanisms for the hepatic clearance ofoligopeptides and proteins. In: Audus KL, Raub TJ, eds. Biological Barriers to Protein Delivery. New York: Plenum Press, 1993:339-408.
22. Ziegler K, Polzin G, Frimmer M. Hepatocellular uptake of cyclosporin A by simple diffusion. Biochim Biophys Acta 1988; 938:44-50.
23. Burwen SJ, Jones AL. Hepatocellular processing of endocytosed proteins. J Electron Microsc Tech 1990; 14:140-151.
24. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, Hanano M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci 1988; 77:200-207.
25. Sugiyama Y, Hanano M. Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res 1989; 6:192-202.
26. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51:531-554.
27. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol 1974; 41: 99-128.
28. Fallon RJ, Schwartz AL. Receptor-mediated delivery of drugs to hepatocytes. Adv Drug Deliv Rev 1989; 4:49-63.
29. Cumming DA. Glycosylation of recombinant protein therapeutics: control and functional implications. Glycobiology 1991; 1:115-130.
30. Strickland DK, Kounnas MZ, Argraves WS. LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. Faseb J 1995; 9:890-898.
31. 2-macroglobulin receptor/low density lipoprotein receptor-related protein. J Biol Chem 1995; 270:23713-23719.
32. Murakami T, Misaki M, Masuda S, Higashi Y, Fuwa T, Yata N. Dosedependent plasma clearance of human epidermal growth factor in rats. J Pharm Sci 1994; 83:1400-1403.
33. van Griensven JMT, Burggraaf KJ, Gerloff J, Gunzler WA, Beier H, Kroon R, Huisman LGM, Schoemaker RC, Kluft K, Cohen AF. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther 1995; 57:381-389.
34. van Griensven JMT, Huisman LGM, Stuurman T, Dooijewaard G, Kroon R, Schoemaker RC, Kluft K, Cohen AF. Effect of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 1996; 60:504-511.
35. Kuwabara T, Uchimura T, Takai K, Kobayashi H, Kaboyashi S, Sugiyama Y. Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. J Pharmacol Exper Ther 1995; 273:1114-1122.
36. Bartocci A, Mastrogiannis DS, Migliorati G, Stockert RJ, Wolkoff AW, Stanley ER. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci USA 1987; 84: 6179-6183.
37. Tanaka H, Kaneko T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Drug Metabol Dispos 1991; 19:200-204.
38. Petros WP, Rabinowitz J, Stuart AR, Gilbert CJ, Kanakura Y, Griffin JD, Peters WP. Disposition of recombinant human granulocite-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and auto-logous bone marrow support. Blood 1992; 80:1135-1140.
39. Tanswell P, Heinzel G, Greischel A, Krause J. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exper Ther 1990; 255:318-324.
40. Bauer RJ, Der K, Ottah-Ihejeto N, Barrientos J, Kung AHC. The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in rats. Pharmaceutical Research 1997; 14:224-229.
41. van Dijk MA, Vidarsson G. Monoclonal antibody-based pharmaceuticals. In: In: Crommelin DJA, Sindelar RD, eds. 2nd ed. . , eds. Pharmaceutical Biotechnology. An Introduction for Pharmacists and Pharmaceutical Scientists. 2nd ed. . 2002.
42. Taylor AE, Granger GN. In: Renkin EM, Michel CC, eds. Handbook of Physiology. Bethesda, MD: American Physiological Society, 1984:467-520.
43. Jain RK, Baxter LT. Extravasation and interstitial transport in tumors. In: In: Audus KL, Raub TJ, eds. Biological Barriers to Protein Delivery. New York: Plenum Press, 1993:441-465.
44. Omar BA, Flores SC, McCord JM. Superoxide dismutase. In: In: Kung AHC, Baughman RA, Larrick JW, eds. Therapeutic Proteins. Pharmacokinetics and Pharmacodynamics. New York: W.H. Freeman and Company, 1992: 295-315.
45. Medalion B, Merin G, Aingorn H, Miao H-Q, Nagler A, Elami A, Ishai-Michaeli R, Vlodavski I. Endogenous basic fibroblast factor displaced by heparin from the luminal surface of human blood vessels is preferentially sequestered by injured regions of the vessel wall. Circulation 1997; 95: 1853-1863.
46. Shen BQ, DeGuzman GG, Zioncheck TZ. Characterization of Vascular Endothelial Growth Factor Binding to Rat Liver Sinusoidal Cells in vitro. South San Francisco: Western Regional Meeting of the American Association of Pharmaceutical Scientists, 1997.
47. Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJJ, Schwartz AL. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 1995; 270:24800-24804.
48. Templeton DM. Proteoglycans in cell regulation. Crit Rev Clin Lab Sci 1992; 29:141-184.
49. Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J Biol Chem 1992; 267.
50. Hansen J-B, Sandset PM, Raanaas Huseby K, Huseby N-E, Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76:703-709.
51. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50:803-813.
52. Bennett HPJ, McMartin C. Peptide hormones and their analogues: distribution, clearance from the circulation, and inactivation in vivo. Pharmacol Rev 1979; 30:247-292.
53. Supersaxo A, Hein W, Gallati H, Steffen H. Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res 1988; 5:472-476.
54. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7:167-169.
55. Xie D, Hale VG. Factors affecting the lymphatic absorption of macromolecules following extravascular administration. Pharm Res 1996; 13:S-396.
56. Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, Braeckman RA. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene-modified interleukin-2 in pigs. JPET 2000; 293:248-259.
57. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exper Ther 1997; 283:520-527.
58. Combs DL. Appendix A to monoclonal antibody-based pharmaceuticals. Trastuzumab/Herceptin®. In: Crommelin DJA, Sindelar RD, eds. Pharmaceutical Biotechnology. An Introduction for Pharmacists Pharmaceutical Scientists. 2nd ed. 2002.
59. Hooper S. Pharmacokinetics and pharmacodynamics of intravenous regular human insulin. In: In: Garzone PD, Colburn WA, Mokotoff M, eds. Pharma-cokinetics and Pharmacodynamics. Peptides, Peptoids, and Proteins. Cincinnati, OH: Harvey Whitney Books, 1991:128-137.
60. Woodworth JR, Howey DC, Bowsher RR. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care 1994; 17:64-69.
61. Holford NHG, Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng 1981; 5:273-322.
62. Roskos LK, Cheung EN, Vincent M, Foote M, Morstyn G. Pharmacology of Filgrastim (r-metHuG-CSF). In: In: Morstyn G, Dexter TM, Foote M, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice. New York: Marcel Dekker, 1998:51-71.
63. Mohler M, Cook J, Lewis D, Moore J, Sinicropi D, Championsmith A, Ferraiolo B, Mordenti J. Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug Metabol Dispos 1993; 21:71-75.
64. Mohler MA, Cook JE, Baumann G. Binding proteins of protein therapeutics. In: In: Ferraiolo BL, Mohler MA, Gloff CA, eds. Protein Pharmacokinetics and Metabolism. New York: Plenum Press, 1992:35-71.
65. Baxter RC. Circulating binding proteins for the insulinlike growth factors. Trends Endocrinol Metab 1993; 4:91-96.
66. Clemmons DR. IGF binding proteins and their functions. Mol Reprod Dev 1993; 35:368-375.
67. Baxter RC, Martin JL. Structure of the Mr 140,000 growth hormonedependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity labeling. Proc Natl Acad Sci USA 1989; 86: 6898-6902.
68. Clemmons DR, Dehoff MH, Busby WH, Bayne ML, Cascieri MA. Competition for binding to IGFBP-2, 3, 4 and 5 by the insulin-like growth factors and IGF analogs. Endocrinology 1992; 132:890-895.
69. Cohen KL, Nissley SP. The serum half-life of somatomedin activity: Evidence for growth hormone dependence. Acta Endocrinol 1976; 83:243-258.
70. Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenous insulin-like growth factor I and II in normal and hypophy-sectomized rats. J Clin Invest 1986; 77:1768-1775.
71. Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 1986; 77:1817-1823.
72. Leung DW. Growth hormone receptor and serum binding: purification, clonong and expression. Nature 1987; 330:537-543.
73. Baumann G, Amburn K, Shaw MA. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology 1988; 122:976-984.
74. Baumann G, Shaw MA, Buchanan TA. In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism 1988; 38:330-333.
75. Boxenbaum H. Time Concepts in physics, biology and pharmacokinetics. J Pharm Sci 1986; 75:1053-1062.
76. Dedrick RL. Animal Scale-Up. J Pharmacokinet Biopharm 1973; 1:435-461.
77. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8:1351-1359.
78. Pan Y-CE, Stern AS, Familletti PC, Khan FR, Chizzonite R. Stuctural characterization of human interferon gamma. Eur J Biochem 1987; 166:145-149.
79. Rinderknecht E, Burton LE. Biochemical characterization of natural and recombinant IFN-gamma. In: In: Kirchner H, Schellenkens H, eds. The Biology of the Interferon System 1984. Amsterdam: Elsevier, 1985:397-402.
80. Rinderknecht E, O'Connor BH, Rodriguez H. Natural human interferongamma: complete amino acid sequence and determination of sites of glycosylation. J Biol Chem 1984; 259:6790-6797.
81. Kukuruzinska MA, Lennon K. Protein N-glycosylation: molecular genetics and functional significance. Crit Rev Oral Biol Med 1998; 9:415-448.
82. Reuter G, Gabius H-J. Eukariotic glycosylation: whim of nature or multipurpose tool? Cell Mol Life Sci 1999; 55:386-422.
83. Stoudemire JB. Pharmacokinetics and metabolism of hematopoietic proteins. In: In: Ferraiolo BL, Mohler MA, Gloff CA, eds. Protein Pharmacokinetics and Metabolism. New York: Plenum Press, 1992:189-222.
84. Ogez JR, van Reis R, Paoni N, Builder SE. Recombinant human tissueplasminogen activator: biochemistry, pharmacology, and process development. In: Garzone PD, Colburn WA, Mokotoff M, eds. Peptides, Peptoids, and Proteins. Cincinnati: Harvey Whitney Books, 1991:170-188.
85. Tanswell P. Tissue-type plasminogen activator. In: In: Kung AHC, Baughman RA, Larrick JW, eds. Therapeutic Proteins. Pharmacokinetics and Pharmacodynamics. New York: W.H. Freeman and Company, 1992:255-281.
86. Bauer RJ, Winkelhake JL, Young JD, Zimmerman RZ. Protein drug delivery by programmed pump infusion: Interleukin-2. In: In: Kung AHC, Baughman RA, Larrick JW, eds. Therapeutic Proteins. Pharmacokinetics and Pharmaco-dynamics. New York: W.H. Freeman and Company, 1992:239-253.
87. Knauf MJ, Bell DP, Hirtzer P, Luo Z-P, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant inter-leukin-2 chemically modified with water-soluble polymers. J Biological Chem 1988; 263:15064-15070.
88. Demignot S, Domurado D. Effect of prosthetic sugar groups on the pharma-cokinetics of glucose-oxidase. Drug Des Deliv 1987; 1:333-348.
89. Zoon K, Stein K, Bekisz J, Schwieterman A. Immune Reactions Against Therapeutic and Diagnostic Biological Products. Meeting of the Biological Response Modifiers Advisory Committee, Bethesda, MD, 1999.
90. Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL. A Phase I study of recombinant interleukin-2 plus recombinant A-interferon. Cancer Res 1988; 48.
91. Konrad M, Childs A, Merigan T, Bordon E. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol 1987; 7:365-375.
92. ser. J Interferon Res 1989; 9(suppl 1):S51-S60.
93. Working PK. Potential effects of antibody induction by protein drugs. In: Ferraiolo BL, Mohler MA, Gloff CA, eds. Protein Pharmacokinetics and Metabolism. New York: Plenum Press, 1992:73-92.
94. Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Fincke JM. Modification of human leucocyte interferon pharmacology with monoclonal antibody. Cancer Res 1985; 45:2421-2424.
95. Sell S. Immunology, Immunopathology and Immunity. Amsterdam: Elsevier, 1987.
96. Takagi A, Masuda H, Takakura Y, Hashida M. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J Pharmacol Exper Ther 1995; 275:537-543.
97. Arendshorst WJ, Navar LG. Renal circulation and glomerular hemodynamics. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. Boston: Little, Brown, 1988:65-117.
98. Jusko WJ, Ko HC. Pharmacodynamics and drug action. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56:406-419.
99. Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: In: Reid RE, ed. Peptide and Protein Drug Analysis. New York: Marcel Dekker, 2000:633-669.
100. Marks DL, Gores GJ, LaRusso NF. Hepatic processing of peptides. In: In: Taylor MD, Amidon GL, eds. Peptide-based Drug Design. Controlling Transport and Metabolism. Washington, DC: American Chemical Society, 1995: 221-248.